The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis (OPPORTUNITY)
Efficacy and Safety of Somatropin in Adult Patients on Chronic Haemodialysis
Sponsor: Novo Nordisk A/S
Terminated
See termination reason in detailed description
Other terminated trials from Novo Nordisk A/S
Other Chronic Kidney Disease trials with similar outcome
A PHASE3 clinical study on Chronic Kidney Disease and End-Stage Renal Disease, this trial is terminated or withdrawn. The trial is conducted by Novo Nordisk A/S and has accumulated 9 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
May 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Feb 2017 — May 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Jul 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .